Fermín-Martínez Carlos A, Ramírez-García Daniel, Antonio-Villa Neftali Eduardo, Espinosa Jerónimo Perezalonso, Aguilar-Ramírez Diego, García-Peña Carmen, Gutiérrez-Robledo Luis Miguel, Seiglie Jacqueline A, Bello-Chavolla Omar Yaxmehen
Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico.
MD/PhD (PECEM) Program, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
NPJ Aging. 2025 Jun 21;11(1):52. doi: 10.1038/s41514-025-00232-1.
We validated AnthropoAge, a biological age (BA) metric, for prediction of mortality and age-related outcomes using harmonized data from the US, England, Mexico, Costa Rica, and China. We estimated AnthropoAge and AnthropoAgeAccel as proxies of BA and age acceleration using body mass index and waist-to-height ratio. We compared mortality prediction of AnthropoAge vs. chronological age (CA) using Cox models and assessed its association with age-related outcomes with generalized estimating equations. Among 57,080 participants aged 50-94 years, AnthropoAgeAccel (c-statistic 0.806) improved mortality prediction of CA (0.803) and identified distinct aging trends for each country. Accelerated aging (AnthropoAgeAccel>0) increased mortality risk by ~37% independently of age and covariates, and predicted health deterioration, new deficits in activities of daily living, and age-related diseases. AnthropoAge is a robust BA metric with potential applications in identifying functional deficits, health decline, and mortality risk. However, it requires further validation and potential recalibration for broader applicability in underrepresented populations like Latin America.
我们使用来自美国、英国、墨西哥、哥斯达黎加和中国的协调数据，验证了一种生物年龄（BA）指标AnthropoAge用于预测死亡率和与年龄相关的结局。我们使用体重指数和腰高比估计AnthropoAge和AnthropoAgeAccel作为BA和年龄加速的代理指标。我们使用Cox模型比较了AnthropoAge与实际年龄（CA）对死亡率的预测，并使用广义估计方程评估了其与年龄相关结局的关联。在57080名年龄在50 - 94岁的参与者中，AnthropoAgeAccel（c统计量为0.806）改善了CA对死亡率的预测（0.803），并确定了每个国家不同的衰老趋势。加速衰老（AnthropoAgeAccel>0）独立于年龄和协变量使死亡风险增加约37%，并预测了健康恶化、日常生活活动中的新缺陷以及与年龄相关的疾病。AnthropoAge是一种强大的BA指标，在识别功能缺陷、健康衰退和死亡风险方面具有潜在应用。然而，它需要进一步验证和可能的重新校准，以便在拉丁美洲等代表性不足的人群中更广泛地适用。
